Ensuring consistent product quality: A key manufacturing challenge in cell and gene therapy vs. advanced biologics
04 May 2026
Cell Therapy Manufacturing
- What experimental designs are required to transform novel findings into robust preclinical datasets that withstand rigorous scrutiny regarding clinical translatability?
- How can research programs simultaneously advance novel mechanistic hypotheses while satisfying the rigorous demands for independent validation and toxicological safety?
- What are the prevalent statistical or experimental shortcomings in early-stage data packages that typically lead to failure during external scientific diligence?
- How can preclinical studies be designed to demonstrate that a novel target offers a distinct biological impact or improved efficacy profile relative to established therapeutic modalities?
